|Description||APS-2-79 is a small molecule antagonist of MEK phosphorylation by RAF through direct binding of the KSR active site, and antagonizes oncogenic Ras signalling (IC50 value 120 nM against ATP-biotin probe-labelling of KSR2).|
|Synonyms||6,7-Dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine; APS-2-79; APS 2-79; APS2-79; APS-279; APS 279; APS279.|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
|Boiling Point||528.6±50.0 °C at 760 Torr|
Trametinib is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM and no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.
Cobimetinib (R-enantiomer) is a selective inhibitor of MEK. It is also known as mitogen activated protein kinase kinase (MAPKK) and is a key component of the RA...
RO5126766, also known as CH5126766, is a protein kinase inhibitor specific for the Raf and MEK mitogen-activated protein kinases (MAPKs) with potential anti-ne...
Cobimetinib, also known as GDC-0973 and XL-518, is a novel selective MEK inhibitor, and the IC50value against MEK1 is 4.2 nM, with potential antineoplastic acti...
AZD8330 is an orally active, selective MEK inhibitor with potential antineoplastic activity. AZD8330 specifically inhibits mitogen-activated protein kinase kina...
GDC-0623 is an orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated pro...
Selumetinib, also known as AZD6244, is an orally bioavailable small molecule with potential antineoplastic activity. Selumetinib inhibits mitogen-activated prot...
cobimetinib, also known as GDC-0973 and XL-518, is an orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1)...
Selective dual MEK5 and ERK5 (or BMK1) kinase inhibitor, with IC50 values of 1.5, 59, 580 and >6200 nM for MEK5, ERK5, TGFbR1 and other closely related kinases ...
Refametinib R enantiomer
Refametinib R enantiomer is a potent, selective and allosteric inhibitor of MEK1/2 in enzyme inhibition assays. It has been reported to inhibit MEK activity and...
Cobimetinib racemate is a selective inhibitor of MEK. It is also known as mitogen activated protein kinase kinase (MAPKK) and is a key component of the RAS/RAF/...
PD98059 is a potent and selective inhibitor of MAP kinase kinase (also known as MAPK/ERK kinase or MEK kinase). It mediates its inhibitory properties by binding...
Selective dual MEK5 kinase inhibitor, with IC50 values of 4.3, 810, 1800, and >6300 nM for MEK5, ERK5, TGFbR1 and other closely related kinases respectively.
RO4987655 is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK ...
APS-2-79 is a small molecule antagonist of MEK phosphorylation by RAF through direct binding of the KSR active site, and antagonizes oncogenic Ras signalling (I...
TAK-733 is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. MEK inhibitor TAK-733 selectively b...
SL327 is a MEK inhibitor. SL327 blocks acquisition but not expression of lithium-induced conditioned place aversion. SL327 had no affect on acquisition, expres...
Pimasertib, also known as AS703026, SAR245509, MSC1936369B, is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineop...
Refametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor RDEA119...
SMK-17 is a MEK1/2 inhibitor. It can inhibit MEK1 kinase activity in a non-ATP-competitive manner and it is highly selective to MEK1 and 2. SMK-17 can inhibit t...